STC-15 will be evaluated in a Phase I study to treat cancer patients. Credit: National Cancer Institute on Unsplash.

Biotechnology company STORM Therapeutics has dosed the first participant in a Phase I study of its first-in-class clinical candidate STC-15.

The multi-centre, open-label, first-in-human Phase I study has been designed for systematically evaluating STC-15’s safety, pharmacokinetics, pharmacodynamics, target engagement, biomarkers related to mechanism, and anti-tumour efficacy in solid tumour patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will assess multiple ascending daily oral doses of STC-15 in Q3W treatment cycles, with dose levels determined by a modified Fibonacci algorithm.

Nearly 40 to 60 participants are expected to be enrolled in the study.

STC-15 is an orally bioavailable, small molecule that inhibits METTL3, an RNA methyltransferase which is implicated in oncology and other diseases.

It is said to be the first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company stated that STC-15’s preclinical activity was shown through direct cytotoxic and anti-cancer immune response mechanisms in solid tumour and leukaemia models.

In addition, the clinical candidate had shown to inhibit tumour growth through anti-cancer immune responses such as changes in interferon signalling and synergy with T cell checkpoint blockade.

STORM Therapeutics CEO Dr Jerry McMahon said: “This is a major milestone for STORM as we enter clinical development with our lead candidate STC-15 and continue progressing a pipeline targeting RNA modifying enzymes beyond METTL3.

“We intend to exhibit preclinical data related to STC-15 at future medical conferences this year as we execute our Phase 1 study in patients with solid tumours.

“We anticipate presenting results from our Phase I study in 2023.”